Results

1–2 of 2 results for Dean Eliott

Timing of Ocular Adverse Events in Pooled Analysis of Two Phase 3 Trials of Revakinagene Taroretcel (NT-501) in Macular Telangiectasia Type 2
Dean Eliott, MD
Annual Meeting Talks
2025
Retinal Detachment Take-Home Panel
Dean Eliott, MD
Annual Meeting Talks
2019